Quantbot Technologies LP Buys 10,227 Shares of Chemed Corporation $CHE

Quantbot Technologies LP lifted its position in Chemed Corporation (NYSE:CHE) by 678.6% during the 3rd quarter, according to its most recent disclosure with the SEC. The fund owned 11,734 shares of the company’s stock after purchasing an additional 10,227 shares during the period. Quantbot Technologies LP owned about 0.08% of Chemed worth $5,254,000 as of its most recent SEC filing.

Several other hedge funds also recently made changes to their positions in CHE. Geneos Wealth Management Inc. grew its holdings in Chemed by 330.4% in the 1st quarter. Geneos Wealth Management Inc. now owns 99 shares of the company’s stock worth $61,000 after acquiring an additional 76 shares during the last quarter. Brighton Jones LLC purchased a new stake in shares of Chemed during the second quarter worth about $224,000. Bessemer Group Inc. boosted its holdings in shares of Chemed by 7.7% during the second quarter. Bessemer Group Inc. now owns 1,023 shares of the company’s stock worth $499,000 after purchasing an additional 73 shares during the period. Atria Investments Inc grew its stake in shares of Chemed by 0.6% in the second quarter. Atria Investments Inc now owns 4,259 shares of the company’s stock worth $2,074,000 after purchasing an additional 25 shares during the last quarter. Finally, Impact Partnership Wealth LLC purchased a new position in Chemed during the 2nd quarter valued at about $214,000. 95.85% of the stock is owned by hedge funds and other institutional investors.

Chemed Trading Up 3.4%

Shares of Chemed stock opened at $410.14 on Friday. Chemed Corporation has a 12 month low of $385.00 and a 12 month high of $623.60. The firm has a market capitalization of $5.81 billion, a P/E ratio of 22.33, a P/E/G ratio of 2.00 and a beta of 0.44. The business has a fifty day simple moving average of $446.06 and a two-hundred day simple moving average of $443.90.

Chemed (NYSE:CHE) last released its earnings results on Wednesday, February 25th. The company reported $6.42 earnings per share for the quarter, missing analysts’ consensus estimates of $7.02 by ($0.60). Chemed had a return on equity of 24.70% and a net margin of 10.48%.The business had revenue of $639.34 million during the quarter, compared to analysts’ expectations of $659.09 million. During the same period in the prior year, the company earned $6.83 earnings per share. The firm’s quarterly revenue was down .1% compared to the same quarter last year. Chemed has set its FY 2026 guidance at 23.250-24.250 EPS. Analysts predict that Chemed Corporation will post 21.43 earnings per share for the current year.

Chemed Dividend Announcement

The firm also recently announced a quarterly dividend, which will be paid on Friday, March 13th. Stockholders of record on Monday, February 23rd will be issued a dividend of $0.60 per share. This represents a $2.40 annualized dividend and a dividend yield of 0.6%. The ex-dividend date is Monday, February 23rd. Chemed’s dividend payout ratio (DPR) is presently 13.06%.

Chemed News Summary

Here are the key news stories impacting Chemed this week:

• Positive Sentiment: Oppenheimer lowered its price target but kept an “outperform” rating (PT cut to $500), signaling some analysts still see multi‑quarter upside despite the recent miss. Oppenheimer PT/Rating
• Neutral Sentiment: RBC reaffirmed a “sector perform” rating and set a $422 target (down from $572), reflecting a more cautious stance but not a full downgrade; this indicates mixed analyst conviction. RBC note
• Neutral Sentiment: Chemed issued FY‑2026 EPS guidance of $23.25–$24.25 (roughly in line but slightly below consensus), and said ~55% of 2026 earnings are likely back‑half weighted as it executes transition initiatives — guidance tempers but does not eliminate investor concern. Earnings release / guidance
• Neutral Sentiment: Full Q4 earnings and conference-call transcripts were posted (Seeking Alpha, Yahoo, others); these provide management commentary on margin compression, VITAS trends and cash‑flow dynamics for investors doing deeper diligence. Earnings call transcript
• Negative Sentiment: Zacks highlights the headline: Q4 EPS and revenue missed consensus, margins contracted and the FY‑2026 EPS outlook came in below street expectations — the earnings shock was the primary catalyst for the sharp share drop. Zacks: Earnings & margins miss
• Negative Sentiment: Detailed quarter metrics (QuiverQuant) show revenue and EPS declines, steeper drops in operating cash flow and lower cash balances — these raise near‑term liquidity and execution risk concerns for investors. QuiverQuant: Financial details
• Negative Sentiment: Johnson Fistel announced an investigation into possible claims tied to Chemed executives — potential litigation risk can amplify selling pressure and valuation uncertainty. GlobeNewswire: Investigation notice
• Negative Sentiment: BofA cut Chemed to neutral after the Q4 miss — another sign of weakening analyst conviction that can pressure sentiment until evidence of margin/cash‑flow stabilization appears. MSN / BofA note

Analyst Upgrades and Downgrades

Several equities research analysts have weighed in on the company. Weiss Ratings reiterated a “hold (c-)” rating on shares of Chemed in a report on Wednesday, January 21st. Oppenheimer decreased their target price on Chemed from $580.00 to $500.00 and set an “outperform” rating for the company in a report on Friday. Jefferies Financial Group cut shares of Chemed from a “buy” rating to a “hold” rating in a report on Thursday, January 22nd. Finally, Royal Bank Of Canada reissued a “sector perform” rating and set a $422.00 price objective (down from $572.00) on shares of Chemed in a research report on Friday. Two analysts have rated the stock with a Buy rating and four have given a Hold rating to the company. According to data from MarketBeat.com, the company has a consensus rating of “Hold” and an average price target of $498.00.

About Chemed

Chemed Corporation is a diversified provider of essential home services and healthcare solutions in the United States. Headquartered in Cincinnati, Ohio, the company operates through two principal business segments—Roto-Rooter and Vitas Healthcare. Since its founding in 1974, Chemed has built a reputation for reliability and expertise, serving both residential and commercial customers across a broad range of markets.

The Roto-Rooter segment offers a comprehensive suite of plumbing, drain cleaning and water restoration services.